Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.

What Was Tested

This controlled clinical trial looks at Gastrin-Releasing Peptide.

The main goal of their study was to characterise the activity of BIM26226 as a peripheral gastrin releasing peptide (GRP) receptor antagonist in healthy human subjects and to determine if endogenous GRP is a physiological regulator of gastric acid secretion and gastrin release.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, men only.

In part II, subjects received BIM26226 or saline during oral meal ingestion or modified sham feeding.

In part III, subjects received an acidified meal in the presence and absence of BIM26226 in a two period crossover design.

How the Study Was Run

The researchers set it up as a double-blind and crossover study.

Neither the participants nor the staff measuring them knew who was on Gastrin-Releasing Peptide, so expectations could not easily colour the readings.

In the crossover set-up each of the participants took both Gastrin-Releasing Peptide and the comparison in turn, acting as their own control.

Their study consisted of three parts.

In addition, gastrin and somatostatin mRNA were measured in biopsy specimens during saline and BIM26226 infusion.

What Was Measured

PubMed files the paper under topics including Analysis of Variance, Blotting, Northern, Bombesin, Eating, Gastric Acid, Gastric Acidity Determination and Gastrin-Releasing Peptide.

What This Means in Plain Language

The paper is a double-blind and crossover study of Gastrin-Releasing Peptide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2001 (Gut), a journal based in England.

More context: all human trials.